

New York State Medicaid Drug Utilization Review (DUR) Board Meeting
Room 2, Concourse Level, Empire State Plaza, Albany NY
May 18, 2023
9:00am to 4:00pm

The meeting will be available for public viewing as a live and archived webcast
[Department of Health Events and Webcasts](#)

9:00 – 9:15 **Welcome and Introductions**

9:15 – 10:45 **Public Comment**

10:45 – 12:45 **Preferred Drug Program (PDP) Review**

The DUR Board will review the therapeutic classes listed below, as they pertain to the PDP ([NYS Public Health Law, Sections 272 and 273](#)), and recommend drugs for preferred or non-preferred status. The review may also include updates to clinical criteria or coverage parameters. The Preferred Drug List (PDL), which includes preferred or non-preferred status and clinical criteria or coverage parameters for each therapeutic class, may be viewed at: [NYRx Preferred Drug List](#). For therapeutic classes currently subject to the PDP, the DUR Board will only consider clinical information, which is new since the previous review of the therapeutic class and then consider financial information.

1. Angiotensin Receptor Blockers
Previous Review date: 4/15/2011
2. Angiotensin Receptor Blocker Combinations
Previous Review date: 11/5/2020
3. Triglyceride Lowering Agents
Previous Review date: 5/13/2021
4. Anticonvulsants – Other
Previous review date: 7/15/2021
5. Selective Serotonin Reuptake Inhibitors
Previous review date: 4/27/2016
6. Psoriasis Agents – Topical
Previous review date: 4/22/2015
7. Dipeptidyl Peptidase 4 Inhibitors
Previous review date: 4/26/2018



-
8. Glucagon Agents
Previous review date: 7/14/2022
 9. Glucagon-like Peptide 1 Agonists
Previous review date: 5/12/2022
 10. Proton Pump Inhibitors
Previous review date: 4/19/2012
 11. Erythropoiesis Stimulating Agents
Previous review date: 5/16/2019
 12. Immunosuppressives – Oral
Previous review date: 7/23/2020
 13. Antihistamines – Ophthalmic
Previous review date: 4/26/2018
 14. Urinary Tract Antispasmodics
Previous review date: 4/22/2015
 15. Anticholinergics / COPD Agents
Previous review date: 5/12/2022
 16. Antihistamines – Second Generation
Previous review date: 4/27/2016
 17. Beta 2 Adrenergic Agents – Inhaled Long Acting
Previous review date: 4/27/2016

12:45 – 2:45 **Lunch / Executive Session (PDP Financial Reviews)**

2:45 – 3:45 **Preferred Drug Program (PDP) Recommendations**

3:45 – 4:00 **Final Comments and Adjournment**

The agenda timeline is subject to change based on meeting proceedings.

Additional Information

Parties interested in providing public comments, during the DUR Board meeting, must complete the registration process by May 10, 2023. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov (please reference DUR Board Meeting Speaker Request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes), and the total comment period will not exceed ninety (90) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment to meet agenda timelines and accomplish meeting objectives.

Written statements must be received in an electronic format by May 10, 2023. Written statements should summarize key points and may not exceed two (2) pages in length. Any studies cited should be referenced, with the primary source of funding included.

Clinical information must be submitted in an electronic format by May 4, 2023, or the DUR Board may not have ample time to review the information.

All information must be sent to the DOH. Interested parties should not contact or send any information directly to DUR Board members.

Other Meeting Locations

University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Abbott Hall
Buffalo, NY 14214

SUNY Global Center
116 East 55th Street, New York, NY 10022